XML 49 R33.htm IDEA: XBRL DOCUMENT v3.22.2
Revenue - Additional Information (Details)
$ in Thousands, segment in Millions
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2022
USD ($)
dose
Mar. 31, 2022
USD ($)
Jun. 30, 2021
USD ($)
Jun. 30, 2022
USD ($)
dose
Jun. 30, 2021
USD ($)
Dec. 31, 2021
USD ($)
dose
Jul. 31, 2022
dose
segment
Revenue Recognition              
Billed contracts receivable | $ $ 165,600     $ 165,600   $ 419,700  
Unbilled contracts receivable | $ 29,000     29,000   $ 35,300  
Revenues | $ 185,925   $ 298,017 889,896 $ 745,246    
Milestone payment recognized | $ $ 20,000     $ 20,000      
Amended and Restated UK Supply Agreement | Subsequent Events              
Revenue Recognition              
Purchase agreement, number of vaccine doses             60,000,000
Amended and Restated UK Supply Agreement | Subsequent Events | Minimum              
Revenue Recognition              
Number of doses of vaccine to be distributed             1,000,000
Amended and Restated UK Supply Agreement | Subsequent Events | Maximum              
Revenue Recognition              
Number of doses of vaccine to be distributed             15,000,000
U.S. government partnership (“OWS”)              
Revenue Recognition              
Purchase agreement, number of vaccine doses 3,000,000     3,000,000      
U.S. government partnership (“OWS”) | Subsequent Events              
Revenue Recognition              
Purchase agreement, number of vaccine doses             3,000,000
Number of doses of vaccine to be distributed             200,000
Additional purchase option, number of doses | segment             9.8
U.S. government partnership (“OWS”) | Subsequent Events | Maximum              
Revenue Recognition              
Number of doses of vaccine to be distributed             100,000,000
Gavi Advance Purchase Agreement SIIPL              
Revenue Recognition              
Number of doses of vaccine to be distributed           1,100,000,000  
Milestone payment recognized | $   $ 350,000       $ 350,000  
Gavi Advance Purchase Agreement- COVAX Facility              
Revenue Recognition              
Number of doses of vaccine to be distributed           350,000,000  
European Commissions ("EC")              
Revenue Recognition              
Purchase agreement, number of vaccine doses 70,000,000     70,000,000      
Number of doses of vaccine to be distributed 100,000,000     100,000,000      
Additional purchase option, number of doses 100,000,000     100,000,000      
Number of doses, remaining 42,000,000     42,000,000      
European Commissions ("EC") | Minimum              
Revenue Recognition              
Number of doses of vaccine to be distributed 20,000,000     20,000,000      
European Commissions ("EC") | Maximum              
Revenue Recognition              
Number of doses of vaccine to be distributed 200,000,000     200,000,000      
European Commissions ("EC") | Subsequent Events              
Revenue Recognition              
Purchase agreement, number of vaccine doses             65,000,000
Number of doses, cancelled             5,000,000
Sales-Based Royalties              
Revenue Recognition              
Revenues | $ $ 1,700   $ 23,500 $ 9,200 $ 23,500    
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-07-01              
Revenue Recognition              
Amount of transaction price not yet satisfied | $ $ 5,000,000     $ 5,000,000      
Remaining performance obligation, expected timing of satisfaction, period 12 months     12 months